SWOG clinical trial number
SWOG-8515
Reactivated (unfavorable histology only): 4/15/90, Temporarily Closed (unfavorable histology only): 11/1/89 Evaluation of Menogaril (NSC-269148) in Non-Hodgkin's Lymphoma
Closed
Phase
Accrual
97%
Published
Abbreviated Title
Reactivated (unfavorable histology only): 4/15/90, Temporarily Closed (unfavorable histology only): 11/1/89 Evaluation of Menogaril (NSC-269148) in Non-Hodgkin's Lymphoma
Activated
03/15/1988
Closed
12/15/1991
Research committees
Lymphoma
Publication Information Expand/Collapse
1999
Phase II trial of menogaril in non-Hodgkin's lymphomas: A Southwest Oncology Group trial.
Other Clinical Trials
SWOG Clinical Trial Number
S2506
MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
74%
Open
Phase